Accessibility Menu
Avicanna logo

Avicanna(OTC) AVCNF

Market Cap$12.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-97%
5 Year-88%
1 Year-54%
1 Month-1%
$0.09
-2.06%
-0.00Today
Avicanna last closing stock price
MetricPriceDate
Last closeUSD 0.092026-08-31
Avicanna stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.39%USD 0.092026-08-24
1 month-0.52%USD 0.092026-07-31
3 month+2.81%USD 0.092026-06-02
Year to date-43.11%USD 0.162025-12-31
1 year-54%USD 0.202025-08-29
3 year-70.49%USD 0.312023-09-01
5 year-87.87%USD 0.762021-09-01
Since inception-96.64%USD 2.752019-09-03

Avicanna Financials at a Glance

Market Cap

$12.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$25.33M

Net Income (TTM)

-CA$3.91M

EPS (TTM)

-$0.02

P/E Ratio

-3.92

Dividend

$0.00

Beta (Volatility)

0.69 (Low)

Price

$0.09

Volume

600

Open

$0.09

Previous Close

$0.09

Daily Range

$0.09 - $0.09

52-Week Range

$0.07 - $0.24

Estimated Earnings Date

Nov 13, 2026

AVCNF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Avicanna

Avicanna Inc. is a biopharmaceutical company focused on the research and development of scientifically-backed products for the global consumer health and pharmaceutical sectors. The company is in its commercial phase and collaborates with Canadian academic and medical institutions to advance its innovative product offerings.

Products and Services
  • RHO Phyto: Medical and wellness products with cannabinoids like CBD, CBG, and THC
  • Pura H&W and Pura Earth: Functional CBD-infused derma-cosmetic and topical products
  • Aureus: Cannabis and hemp-derived goods, including extracts and bulk formulations
Growth Outlook
  • Partnerships with academic institutions enhance research capabilities
  • Expansion into pharmaceutical solutions for chronic pain and neurological disorders
  • Development of cannabinoid-based treatments for COVID-19-related lung inflammation
Financial Highlights
  • Q2 2026 revenue of CAD 5.64 million, showing strong market demand
  • Gross profit margin of 53.1% indicates effective cost management
  • Trailing twelve months (TTM) gross profit margin of 51.9% reflects consistent performance
Avicanna Inc. is positioned in a rapidly growing industry, leveraging scientific research to develop a diverse range of cannabinoid-based products. The company's strategic partnerships and innovative product lines aim to address significant health challenges, potentially leading to substantial market opportunities. Recent financial performance highlights a solid revenue stream and effective cost management, suggesting a promising outlook for future growth.
AI Generated • Aug 26, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

112

CEO

Aras Azadian, MBA

Website

www.avicanna.com

Headquarters

Toronto, ON M5G 1V2, CA

AVCNF Financials

Key Financial Metrics (TTM)

Gross Margin

51.87%

Operating Margin

-14.76%

Net Income Margin

-15.45%

Return on Equity

-108.44%

Return on Capital

-95.51%

Return on Assets

-16.21%

Earnings Yield

-25.51%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$12.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

134.38M

Volume

600

Avg. Volume

68.01K

Financials (TTM)

Gross Profit

CA$13.14M

Operating Income

-CA$3.74M

EBITDA

-CA$3.04M

Operating Cash Flow

-CA$3.16M

Capital Expenditure

-CA$206.96K

Free Cash Flow

-CA$3.36M

Cash & ST Invst.

CA$200.50K

Total Debt

CA$169.64K

Avicanna Performance Analysis

Avicanna annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 3,109,32119.3%
20232023-12-31CAD 12,441,020300.1%
20242024-12-31CAD 18,583,89049.4%
20252025-12-31CAD 18,234,383-1.9%
Avicanna sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-303.9%
Q42025-12-313.1%
Q12026-03-311.6%
Q22026-06-30-15.8%
Avicanna annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.17-46.2%
20232023-12-31CAD -0.07-60.4%
20242024-12-31CAD -0.03-57.8%
20252025-12-31CAD -0.02-39.2%
Avicanna sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-84.1%
Q42025-12-3132.8%
Q12026-03-3137.2%
Q22026-06-30-65.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$5.64M

-8.4%

Gross Profit

CA$3.00M

-4.2%

Gross Margin

53.11%

N/A

Market Cap

$12.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$110.65K

N/A

Employees

112

N/A

Net Income

-CA$1.02M

-45.7%

EBITDA

-CA$917.53K

-81.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$200.50K

-3.4%

Total Debt

CA$169.64K

+357.3%

Accounts Receivable

CA$4.09M

+47.4%

Inventory

CA$4.61M

+5.2%

Long Term Debt

CA$0.00

N/A

Short Term Debt

CA$169.64K

+163.7%

Return on Assets

-16.21%

N/A

Return on Invested Capital

-25.76%

N/A

Free Cash Flow

-CA$1.33M

-517.2%

Operating Cash Flow

-CA$1.17M

-796.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IZOZFIzotropic Corporation
$0.17-1.70%
CNTMFFluent Corp.
$0.02-4.93%
MEDIFMediPharm Labs Corp.
$0.06-2.96%
ISCNFIsracann Biosciences Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$219.70-0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.35-0.06%
INTCIntel
$88.98-0.01%
BITOProShares Trust - ProShares Bitcoin ETF
$10.44-0.02%

Questions About AVCNF

What is the current price of Avicanna?

Avicanna is trading at $0.09 per share.

What is the 52-week range for Avicanna?

Over the past 52 weeks, Avicanna has traded between $0.07 and $0.24.

How much debt does Avicanna have?

As of the most recent reporting period, Avicanna reported total debt of CA$119.52K.

How much cash does Avicanna have on hand?

Avicanna reported CA$141.26K in cash and cash equivalents in its most recent financial results.

What is Avicanna’s dividend yield?

Avicanna does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services